1304P - Characteristics of 982 lung cancer patients in Serbia according to the WHO/IASLC classification of lung cancers and subsequent treatment - AVATAR ep...

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Aetiology, epidemiology, screening and prevention
Non-small-cell lung cancer
Basic Scientific Principles
Presenter Dragana Jovanovic
Authors D. Jovanovic1, N. Secen2, Z. Murtezani3, M. Rancic4, V. Kacar-Kukric1, M. Velinovic1, A. Tepavac5, E. Budisin5, Z.G. Andric3, N. Vukobradovic Djoric6
  • 1Institute Of Lung Diseases, Clinical Center of Serbia, 11000 - Belgrade/YU
  • 2Clinic For Pulmonary Oncology - Department For Chemotherapy, Institute for pulmonary diseases of Vojvodina, 21204 - Sremska Kamenica/YU
  • 3Medical Oncology, KBC Bezanijska Kosa, 11000 - Belgrade/YU
  • 4Clinic For Pulmonary Diseases - Knez Selo, Clinical Center Nis, 18000 - Nis/YU
  • 5Clinic For Pulmonary Oncology, Institute for pulmonary diseases of Vojvodina, 21204 - Sremska Kamenica/YU
  • 6Medical, Roche, 11000 - Belgrade/YU



The purpose of this prospective study, conducted over 3 months period, was to analyse demographic and clinicopathological features of lung cancer patients in Serbia, and subsequent treatment approach as well.

Material and methods

The data on lung cancer patients were collected based on specific questionnaire at 4 major centers in Serbia. An analysis of demographic and clinical/ histological features with subsequent treatment was performed in 982 patients (aged over 19 years).


Male to female ratio 709 (72%): 273 (28%), 46% aged < 60 years. Majority were current smokers (68%) and ex-smokers (21%), 11% non-smokers. NSCLC was diagnosed in 80% (789), and SCLC in 19 %. Among NSCLC patients, 71.6 % had stage IIIb and IV. Most common histological subtype was adenocarcinoma (46%), squamous cell carcinoma - 44%, large cell - 4% and the rest NOS and rare subtypes. Neodjuvant therapy was applied in 8%, 19% were operated: 64% of them recieved adjuvant chemotherapy. Most common adjuvant regimens were PE (65%) and platinum/gemcitabine (20%). First line chemotherapy was applied in 91% of stage IIIb and IV NSCLC patients: platinum/etoposide-51% and platinum/gemcitabine-45% were most frequently applied. ECOG PS 0 and 1, was noted in 92%. Second line chemotherapy was given to 27% of patients who recieved 1st line therapy. Most common 2nd line regimens were platinum/gemcitabine (35%), platinum/taxanes (18%), platinum/vinorelbine (13%) and taxanes monotherapy (12.5%). Only 8% recieved pemetrexed or erlotinib. Almost all 2nd line treated patients (93%) had good ECOG PS: 0 and 1. Third line chemotherapy was applied in 22% of those who recieved 2nd line.


This is the largest series of lung cancer patients in Serbia, analized by both, patient characteristics and therapy regimens. Compared with previous similar analysis from 2009, it can be concluded the number of NSCLC patients is increasing, especially in stage IIIb and IV (1.5% per year). Adenocarcinoma rate is also increasing (41% in 2009 vs 45% in 2011). Regarding treatment, we can conclude there is no major progress in treatment options in Serbia.


All authors have declared no conflicts of interest.